Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
about
Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factorsMetabolic control of cancer cell stemness: Lessons from iPS cellsXenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agentsPerspectives of gene combinations in phenotype presentationHuman stem cells for craniomaxillofacial reconstruction.'Above all, do no harm': safeguarding pluripotent stem cell therapy against iatrogenic tumorigenesis.Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion proteinThe nutritional phenome of EMT-induced cancer stem-like cellsInhibition of pluripotent stem cell-derived teratoma formation by small moleculesChemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells.Molecular imaging of induced pluripotent stem cell immunogenicity with in vivo development in ischemic myocardiumMetformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193bActivation of the methylation cycle in cells reprogrammed into a stem cell-like state.The Universal 3D3 Antibody of Human PODXL Is Pluripotent Cytotoxic, and Identifies a Residual Population After Extended Differentiation of Pluripotent Stem CellsImmunogenicity and functional evaluation of iPSC-derived organs for transplantationOne-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metforminMitophagy-driven mitochondrial rejuvenation regulates stem cell fateNuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.Adult Stem Cells and Diseases of Aging.The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.Metabostemness: a new cancer hallmark.Technical approaches to induce selective cell death of pluripotent stem cells.Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment.The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.Novel role of mitochondrial manganese superoxide dismutase in STAT3 dependent pluripotency of mouse embryonic stem cells.Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity.Health benefits of late-onset metformin treatment every other week in mice.Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy.Metformin from mother to unborn child - Are there unwarranted effects?
P2860
Q24633525-1ADCB505-CA2D-4B57-A8E5-43759103F602Q28081608-D604B3F1-EBEE-4E13-8BB1-BB74641ECCD4Q28395443-9658CFB0-7C93-419B-8C9F-4D38EDE62E98Q30450809-DE019930-1449-4B7B-A50F-9F5614526A23Q33788845-6CC0B93C-A4AA-4F89-8045-7D550CFFCA17Q33826992-2CDAD7BB-7E5A-4577-A89D-80BC1621DD10Q34043742-91D00460-7016-4D9D-9545-02BDA1D0A42DQ34100815-80910E22-D042-4E6C-B972-3E005B2589EAQ34362039-7F488E43-BE79-4C70-B4A4-386C6E4BBE5BQ34483548-BB3832EC-EF66-45CE-8116-71845B118B39Q34805318-E4A8684E-E1AA-4221-AA01-5B38E487E93FQ36062114-41553341-49E2-460C-A780-F706619F9E02Q36527529-687013C4-6028-4C5F-A6EF-93586534D24CQ36756141-C9A7824D-1F0A-4D33-AA5E-0E30577C3957Q36882692-752017C3-F1E7-41CD-90D1-1591BEFAEAF4Q37001540-E581121F-BEA8-4782-8B39-A43CB6AD08C2Q37194210-D3CC9658-BA25-40E7-BDF3-AAEC2B7DF9ABQ37420064-C39B8778-94EE-4BE8-845C-AB30AE50FC76Q37711264-11AFBAC7-DC8C-4741-8EBA-C9734E6C6036Q38071479-F728E90F-A78C-4D8A-9FB7-3AC4004C3323Q38261030-F7C0C05C-7E9B-4A27-8BBE-570054FB79FFQ39155502-232C52FF-394A-407E-AFD7-2D3C94BD4E1DQ39247899-3662B3E4-5D4E-4D77-8C1A-06EF79AE2588Q40720253-AC39AA36-593B-43C0-8A4A-15FA364DD401Q41831013-D633D52B-6983-4F01-B377-BB6C20773D87Q41867555-6761FD6D-B166-4CBA-8D61-BAA8D4B1FE1DQ47110103-2DAC08E3-E51D-4508-9A48-2E8AC9E4C392Q47304462-4F3F617F-857A-4A76-8B84-7E7EB72946BBQ55177017-B126A92B-CF31-4F23-BEF3-35BE1330038AQ58700210-CE0257F6-E1EE-45ED-8DA4-8AB78016046B
P2860
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
@ast
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
@en
type
label
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
@ast
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
@en
prefLabel
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
@ast
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
@en
P2093
P2860
P356
P1433
P1476
Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.
@en
P2093
Alejandro Vazquez-Martin
Bruna Corominas-Faja
Cristina Oliveras-Ferraros
Eugeni Lopez-Bonet
Javier A Menendez
Sílvia Cufi
P2860
P2888
P356
10.1038/SREP00964
P407
P577
2012-12-12T00:00:00Z